Printer Friendly

DANNINGER MEDICAL TECHNOLOGY, INC. ANNOUNCES FDA MARKETING CLEARANCE FOR SPINAL SYSTEM AND FORMATION OF ADVISORY BOARD

 DANNINGER MEDICAL TECHNOLOGY, INC. ANNOUNCES FDA MARKETING
 CLEARANCE FOR SPINAL SYSTEM AND FORMATION OF ADVISORY BOARD
 COLUMBUS, Ohio, April 22 /PRNewswire/ -- Danninger Medical Technology, Inc. (NASDAQ: DANN) today made two key announcements concerning its wholly owned subsidiary, Cross Medical Products, Inc. (Cross). First, the U.S. Food and Drug Administration has granted 510(k) marketing clearance for Cross' PWB Lumbosacral Spine System. This action enables Cross to proceed to market with this device. Second, a board of medical advisors has been formed to assist Cross in development of implants and instruments for treatment of spinal disorders.
 Joseph A. Mussey, president and chief executive officer, commented, "Approval of Cross' 510(k) application to market the Lumbosacral Spine System and formation of the Board of Medical Advisors are strategic developments for Cross. Specific efforts to successfully develop implants for the entire spine to treat a wide range of disorders will benefit from medical expertise represented on the advisory board. It is now anticipated that Cross will become a more significant part of Danninger Medical Technology, Inc.'s consolidated future results."
 The U.S. FDA's 510(k) approval has been granted specifically for procedures dealing with hook fixation/attachment to the spine and/or screw fixation/attachment to the sacrum. Cross' device is considered to be equivalent to systems currently being marketed in the United States. This device is fixed/attached to the spine by laminar hooks and/or sacral screws. The 510(k) approval of the PWB Lumbosacral Spine System enables this device to be marketed immediately for cases where it is intended to be fixed/attached to the spine by laminar hooks and/or sacral screws. While FDA approval has been granted to market this device, it does not constitute approval of the device system. This approval does not apply to Cross' Puno/Winter/Byrd Pedicle Screw/Rod System, which continues to be utilized subject to an FDA Investigational Device Exemption.
 The board of medical advisors will assist Cross in the development of implants for the entire spine. All of the board members are active spinal surgeons. Spinal implant devices are used to facilitate fusion of elements of the spine and to treat degenerative diseases, deformities and trauma. It is believed to be the most rapidly growing segment of orthopedic surgery.
 Members of the board of medical advisors include: Dr. Bruce J. Bartie, D.O. (Minneapolis), Dr. J. Abbott Byrd III, M.D. (Norfolk, Va.), Dr. Francis Denis, M.D. (Minneapolis), Dr. John E. Lonstein, M.D. (Minneapolis), Dr. Manuel R. Pinto, M.D. (Minneapolis); Dr. Rolando M. Puno, M.D. (Louisville, Ky.), Dr. Michael D. Smith, M.D. (Minneapolis), and Dr. Robert B. Winter, M.D. (Minneapolis).
 Danninger Medical Technology, Inc. designs, manufactures and markets medical devices that assist patients in their recovery following surgery or trauma. Danninger is a leader in Continuous Passive Motion devices for the knee, hip and hand. Cross Medical Products, Inc., a wholly owned subsidiary of Danninger, manufactures and markets spinal implants subject to specific FDA approvals and orthopedic surgical instrumentation.
 -0- 4/22/92
 /CONTACT: Joseph A. Mussey, president of Danninger, 614-276-8267/
 (DANN) CO: Danninger Medical Technology, Inc. ST: Ohio IN: MTC SU:


CG -- CL019 -- 1354 04/22/92 14:05 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 22, 1992
Words:538
Previous Article:RELIGION NEWS CONFERENCE WITH NEW HEAD OF AUGSBURG FORTRESS
Next Article:NEWPARK EARNINGS RISE 78 PERCENT IN FIRST QUARTER


Related Articles
DANNINGER MEDICAL TECHNOLOGY, INC. ANNOUNCES HIGHER FIRST QUARTER EARNINGS
DANNINGER MEDICAL TECHNOLOGY, INC. ANNOUNCES ADDITION OF TWO KEY MARKETING EXECUTIVES
DANNINGER MEDICAL TECHNOLOGY, INC. ANNOUNCES RECORD SALES FOR 1993; NET LOSS DUE TO PROVISIONS FOR CERTAIN INVENTORY AND ACCOUNTS RECEIVABLE
DANNINGER MEDICAL TECHNOLOGY, INC. ANNOUNCES FDA MARKETING CLEARANCE FOR SHOULDER THERAPY DEVICE
DANNINGER MEDICAL TECHNOLOGY ANNOUNCES FIRST QUARTER RESULTS
DANNINGER MEDICAL TECHNOLOGY, INC. SUBSIDIARY RECEIVES FDA MARKET CLEARANCE FOR ANTERIOR PORTION OF SYNERGY SYSTEM
DANNINGER MEDICAL TECHNOLOGY, INC. REPORTS RECORD FIRST QUARTER SALES
DANNINGER MEDICAL TECHNOLOGY SUBSIDIARY RECEIVES FDA MARKET CLEARANCE FOR POSTERIOR PORTION OF SYNERGY SPINAL SYSTEM AND SPINAL PEDICLE SCREWS
DANNINGER MEDICAL TECHNOLOGY, INC. SUBSIDIARY RECEIVES FDA MARKET CLEARANCE FOR THE SYNERGY SPINAL TITANIUM ANTERIOR SPINAL SYSTEM
Danninger Medical Technology, Inc. Subsidiary Receives FDA Market Clearance for the Synergy Posterior Titanium Spinal System

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters